Taken together, we provide compelling evidence that GLP1 may serve as not only an effective treatment for diabetes management, but also as a promising pharmacotherapy for managing obesity and appetitive behavior. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.